Genic Co., Ltd

As of March 31, 2026, Genic Co., Ltd carries a market capitalization of 244.52B, placing it among publicly traded companies globally. Its enterprise value stands at 241.85B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Genic Co., Ltd's next confirmed earnings release is scheduled for November 12, 2026.

As of March 31, 2026, Genic Co., Ltd has 7.82M shares outstanding.

As of March 31, 2026, Genic Co., Ltd trades at a trailing price-to-earnings ratio of 12.97. The price-to-sales ratio is 2.73, and the price-to-book ratio stands at 5.49.

As of March 31, 2026, Genic Co., Ltd trades at an EV/EBITDA multiple of 14.38 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 2.70 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 16.54 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 241.85B versus a market cap of 244.52B, with the gap driven by net debt and cash on the balance sheet.

As of March 31, 2026, Genic Co., Ltd maintains a current ratio of 1.95, meaning it holds 1.9x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended March 31, 2026, Genic Co., Ltd posted a return on equity (ROE) of 53.67, showing how much profit the company earns on every dollar of shareholder capital. Return on assets (ROA) stands at 34.77, measuring how efficiently the asset base is converted into earnings. The company generates approximately 242.18M in revenue per employee across its workforce of 370.50, a quick read on workforce productivity versus industry peers. Inventory turnover of 7.14 indicates how many times Genic Co., Ltd sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended March 31, 2026, Genic Co., Ltd recorded an income tax benefit of -4.22B rather than an expense, typically from losses, carryforwards, or the release of a tax provision. Taxes are levied on pretax income of 14.63B, leaving 18.85B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 23, 2026, Genic Co., Ltd's stock has declined approximately 20.24% over the past 52 weeks. The 50-day moving average sits at 25,968.40, while the 200-day moving average is 24,079.20.

Over the twelve months ended March 31, 2026, Genic Co., Ltd generated 89.73B in revenue and converted that into 18.85B in net income, yielding earnings per share of 2,408.66. EBITDA reached 16.82B, while operating income came in at 14.63B.

As of March 31, 2026, Genic Co., Ltd holds 5.39B in cash and equivalents against 2.72B in total debt, resulting in a net debt position of -5.34B. Total book value stands at 44.56B, with working capital of 18.94B providing operational flexibility.

Genic Co., Ltd produced 10.54B in operating cash flow over the twelve months ended March 31, 2026. After subtracting -4.82B in capital expenditures, free cash flow totaled 5.71B - equivalent to 729.92 per share.

Over the twelve months ended March 31, 2026, Genic Co., Ltd posted a gross margin of 25.44, reflecting its pricing power and cost economics. The operating margin of 16.30 and net profit margin of 21.00 provide insight into operational efficiency.

These figures cover the twelve months ended March 31, 2026. Free cash flow yield stands at 2.34, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 2.19, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Genic Co., Ltd shareholders.

Genic Co., Ltd's most recent stock split took place on December 27, 2017 with a 97:98 split ratio.

As of March 31, 2026, Genic Co., Ltd has an Altman Z-Score of 9.31, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.